Cambrex Revenue and Competitors

East Rutherford, NJ USA

Location

$241.7M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Cambrex's estimated annual revenue is currently $531M per year.(i)
  • Cambrex received $200.0M in venture funding in April 2007.
  • Cambrex's estimated revenue per employee is $308,362
  • Cambrex's total funding is $241.7M.

Employee Data

  • Cambrex has 1722 Employees.(i)
  • Cambrex grew their employee count by -10% last year.

Cambrex's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Drug substance BU VP Sales and Business Development Europe/AsiaReveal Email/Phone
3
VP, Finance - Drug ProductReveal Email/Phone
4
VP, FacilitiesReveal Email/Phone
5
VP and GM at CambrexReveal Email/Phone
6
Head Solid State ScienceReveal Email/Phone
7
Quality Assurance OfficerReveal Email/Phone
8
ControllerReveal Email/Phone
9
Head Quality and Regulatory ComplianceReveal Email/Phone
10
Vice Direttore di ProduzioneReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Cambrex?

Cambrex is an innovative life sciences company with a refreshingly human approach. Driven by passion, our pharmaceutical products, expertise and technologies accelerate our customers small molecule therapeutics into markets across the world. With over 35 years of active pharmaceutical ingredient (API) development and manufacturing expertise, a growing team of more than 1,200 experts and a strong presence in the USA and Europe, we are tried and trusted across branded and generic API markets. > We put all of our energy and experience into being your partner of choice > We create value for customers through manufacturing excellence, reliable quality and innovative science > Our people are the experts that our customers enjoy working with Our custom development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. We are committed to operating our facilities with the highest standards for regulatory, environmental, health, safety, and security guidelines. We actively incorporate Lean Six Sigma to consistently deliver efficient, high quality, and cost competitive products with less time to market for our clients. We are proud of our long history of regulatory excellence. When you work with Cambrex, you can expect a friendly, energetic and customer-focused team that will deliver your project requirements. And theyll do so with passion and integrity at the core. To experience the Cambrex difference, get in touch.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$241.7M

Total Funding

1722

Number of Employees

$531M

Revenue (est)

-10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cambrex News

2022-04-17 - Cambrex Completes Large-Scale U.S. API Expansion

Cambrex has completed a $50 million expansion of its large-scale active pharmaceutical ingredient (API) manufacturing capabilities at its...

2022-04-13 - Cambrex Completes Large-Scale US API Expansion

Cambrex offers a range of specialized drug substance technologies and capabilities, including biocatalysis, continuous flow, controlled...

2022-04-13 - Expanding API manufacturing operations: Cambrex and ...

Cambrex expands API manufacturing capacity at flagship US facility and Asymchem completes construction of two new Chinese API production...

2019-09-06 - Form PREM14A CAMBREX CORP For: Sep 05

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

2019-08-13 - CAMBREX INVESTOR ALERT By the Former Attorney ...

CAMBREX INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$888.9M27976%N/A

Cambrex Funding

DateAmountRoundLead InvestorsReference
2001-11-30$430.0MCredit FacilityArticle
2004-08-03$0.0MTitle: President CEOArticle
2007-04-09$200.0MUndisclosedJPMorgan Chase Bank N.AArticle